Massive Bio Recognized by White House Cancer Moonshot, Launches $15M Initiative at JPM 2025
Massive Bio is proud to announce its inclusion in the White House Office of Science & Technology Policy’s upcoming Cancer Moonshot Fact Sheet, highlighting its innovative efforts to transform clinical trial access and expedite decentralized trials for cancer patients globally. In conjunction with its participation in the 2025 JPMorgan Healthcare Conference (JPM 2025), the company is launching a $15 million initiative to enhance its AI-powered clinical trial matching platform, establish groundbreaking pre-screening hubs, and expand its patient-centered ‘hub and spoke’ model. These efforts aim to support over 50,000 cancer patients annually, with a goal of reaching 250,000 patients worldwide by 2027.
Massive Bio is pioneering the future of clinical trials with its innovative approach to decentralized research and just-in-time trial activation. By integrating advanced data analytics and a patient-centric ‘hub and spoke’ model, the company is transforming how cancer clinical trials are conducted. The company’s unique platform allows for faster, more efficient trials, making cutting-edge research accessible to patients regardless of location, dramatically reducing timelines and optimizing resource use.
This groundbreaking model has garnered significant recognition, including its inclusion in the White House Office of Science and Technology Policy’s Cancer Moonshot initiative. Massive Bio’s participation highlights the company’s commitment to advancing clinical trials in ways that bring new cancer treatments to the global population faster and more equitably.
Proven Model for Just-in-Time and Decentralized Trials
Massive Bio’s platform enables clinical trials to be conducted remotely and on-demand, ensuring that patients can participate from their homes or local clinics. By combining its ‘hub and spoke’ model with cutting-edge technology, the company streamlines essential clinical trial steps such as patient screening, consent, and enrollment. This approach eliminates the need for patients to travel long distances to participate in trials, which is particularly important for underserved populations who may face geographic, financial, or logistical barriers to care. As a result, trials are not only faster but also more inclusive, addressing long-standing disparities in healthcare access.
Groundbreaking Pre-Screening Hubs and Real-Time Data Analytics
One of the cornerstones of Massive Bio’s strategy is its pre-screening hubs, which leverage genomic profiling and real-world data to proactively identify eligible patients. These hubs significantly shorten time-to-enrollment, ensuring that clinical trials can begin more rapidly and more patients can access cutting-edge treatments.
The real-time data analytics platform further enhances this process by continuously monitoring patient eligibility and trial opportunities. Powered by AI, the system works 24/7 to flag potential participants as new trials become available or as patients’ eligibility evolves, ensuring a constant stream of new participants and faster trial progress.
AI and Data Integration for Improved Trial Access
“We are thrilled to partner with the White House Cancer Moonshot, bridging critical gaps in care and advancing just-in-time and decentralized clinical trials,” said Dr. Selin Kurnaz, CEO and Co-Founder of Massive Bio. “This recognition acknowledges the tireless work of our team and the potential of our platform to bring equitable and faster trial access to patients across the globe.”
Cagatay Culcuoglu, COO/CTO and Co-Founder, added, “Our AI-driven platform integrates real-world data with advanced genomic insights, ensuring that every patient, especially those from underserved and underrepresented communities, can benefit from equitable and efficient access to trials. This is how we reimagine patient-centric clinical research.”
The collaboration with multiple stakeholders—from healthcare providers and pharmaceutical companies to patient advocacy groups—enhances the integration of data and resources. This collaboration creates a seamless patient journey that brings together every piece of the puzzle to ensure that no patient is left behind.
Collaboration for Equitable Access
Massive Bio’s ecosystem is intentionally designed to prioritize underserved and underrepresented populations. Through collaborations with healthcare providers, pharmaceutical sponsors, and patient advocates, the company ensures that clinical trials are not limited by traditional barriers, like access to specialized care or trial locations. This approach helps to overcome historical disparities in clinical trial participation, particularly among racial and ethnic minorities, rural populations, and economically disadvantaged individuals.
Launch at JPM 2025 and Future Outlook
At the 2025 JPMorgan Healthcare Conference, Massive Bio will present its AI-driven, patient-centric platform and the potential impact of its pre-screening hubs. By 2027, the company aims to expand its reach to 250,000 patients annually, further accelerating the fight against cancer and expanding access to life-saving treatments. The $15 million initial investment in this project is expected to fuel the development of a scalable, patient-first solution that bridges the gap between cancer patients and clinical trial opportunities.
The platform’s long-term goal is to close the disparities in trial enrollment and provide just-in-time, decentralized study opportunities to patients, regardless of where they live. With Massive Bio’s focus on improving the clinical trial process, cancer patients will have faster access to more treatments, potentially reducing the timeline for discovering breakthrough therapies.
About Massive Bio
Founded in 2015, Massive Bio is an AI-enabled company committed to transforming the pharmaceutical value chain with innovative solutions that improve patient access to clinical trials and optimize drug development processes. Through its groundbreaking platform, the company facilitates data-driven cancer treatment and fosters value-based oncology decisions. Massive Bio’s work spans the full spectrum of the patient journey, from drug development to commercialization, with a focus on making clinical trials more accessible and inclusive.
The company works with pharmaceutical companies, contract research organizations (CROs), and hospital networks to streamline the clinical trial process, reducing inefficiencies and improving outcomes. Massive Bio is a founding member of CancerX, a public-private partnership supporting the Cancer Moonshot initiative, and has earned recognition from the National Cancer Institute. With over 100 employees across 17 countries, the company is poised to impact the global fight against cancer by bringing innovative solutions to the clinical trial process.
